Kiniksa Pharmaceuticals International, plc
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.48 USD
−43.19 M USD
423.24 M USD
43.34 M
About Kiniksa Pharmaceuticals International, plc
Sector
Industry
CEO
Sanj K. Patel
Website
Headquarters
London
Founded
2024
IPO date
May 24, 2018
Identifiers
2
ISIN GB00BRXB0C07
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of KNSA is 45.88 USD — it has decreased by −0.60% in the past 24 hours. Watch Kiniksa Pharmaceuticals International, plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kiniksa Pharmaceuticals International, plc stocks are traded under the ticker KNSA.
KNSA stock has risen by 2.99% compared to the previous week, the month change is a 7.61% rise, over the last year Kiniksa Pharmaceuticals International, plc has showed a 137.97% increase.
We've gathered analysts' opinions on Kiniksa Pharmaceuticals International, plc future price: according to them, KNSA price has a max estimate of 62.00 USD and a min estimate of 50.00 USD. Watch KNSA chart and read a more detailed Kiniksa Pharmaceuticals International, plc stock forecast: see what analysts think of Kiniksa Pharmaceuticals International, plc and suggest that you do with its stocks.
KNSA reached its all-time high on Feb 2, 2026 with the price of 45.02 USD, and its all-time low was 5.01 USD and was reached on Oct 17, 2019. View more price dynamics on KNSA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
KNSA stock is 5.30% volatile and has beta coefficient of 0.35. Track Kiniksa Pharmaceuticals International, plc stock price on the chart and check out the list of the most volatile stocks — is Kiniksa Pharmaceuticals International, plc there?
Today Kiniksa Pharmaceuticals International, plc has the market capitalization of 3.39 B, it has decreased by −1.36% over the last week.
Yes, you can track Kiniksa Pharmaceuticals International, plc financials in yearly and quarterly reports right on TradingView.
Kiniksa Pharmaceuticals International, plc is going to release the next earnings report on Mar 3, 2026. Keep track of upcoming events with our Earnings Calendar.
KNSA earnings for the last quarter are 0.23 USD per share, whereas the estimation was 0.32 USD resulting in a −28.93% surprise. The estimated earnings for the next quarter are 0.32 USD per share. See more details about Kiniksa Pharmaceuticals International, plc earnings.
Kiniksa Pharmaceuticals International, plc revenue for the last quarter amounts to 180.85 M USD, despite the estimated figure of 167.39 M USD. In the next quarter, revenue is expected to reach 200.64 M USD.
KNSA net income for the last quarter is 18.43 M USD, while the quarter before that showed 17.83 M USD of net income which accounts for 3.38% change. Track more Kiniksa Pharmaceuticals International, plc financial stats to get the full picture.
No, KNSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 13, 2026, the company has 315 employees. See our rating of the largest employees — is Kiniksa Pharmaceuticals International, plc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Kiniksa Pharmaceuticals International, plc EBITDA is 39.64 M USD, and current EBITDA margin is −10.38%. See more stats in Kiniksa Pharmaceuticals International, plc financial statements.
Like other stocks, KNSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kiniksa Pharmaceuticals International, plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kiniksa Pharmaceuticals International, plc technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kiniksa Pharmaceuticals International, plc stock shows the buy signal. See more of Kiniksa Pharmaceuticals International, plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.